Citadel Advisors
VERV

Citadel Advisors’s Verve Therapeutics VERV Stock Holding History

Citadel Advisors’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-190,900
Closed -$2.14M – 14206
2025
Q2 		$2.14M Buy
190,900
+172,300
+926% +$982K ﹤0.01% 5577
2025
Q1 		$85K Sell
18,600
-51,900
-74% -$348K ﹤0.01% 11694
2024
Q4 		$398K Sell
70,500
-46,600
-40% -$263K ﹤0.01% 9070
2024
Q3 		$567K Buy
117,100
+66,500
+131% +$386K ﹤0.01% 7991
2024
Q2 		$247K Buy
50,600
+37,100
+275% +$233K ﹤0.01% 9519
2024
Q1 		$179K Sell
13,500
-24,600
-65% -$326K ﹤0.01% 10497
2023
Q4 		$531K Buy
38,100
+18,400
+93% +$228K ﹤0.01% 7964
2023
Q3 		$261K Buy
19,700
+12,800
+186% +$206K ﹤0.01% 9413
2023
Q2 		$129K Buy
6,900
+3,300
+92% +$55K ﹤0.01% 10549
2023
Q1 		$51.9K Sell
3,600
-5,200
-59% -$102K ﹤0.01% 12098
2022
Q4 		$170K Sell
8,800
-15,200
-63% -$403K ﹤0.01% 10406
2022
Q3 		$824K Buy
24,000
+11,800
+97% +$377K ﹤0.01% 7410
2022
Q2 		$186K Sell
12,200
-9,900
-45% -$153K ﹤0.01% 10786
2022
Q1 		$504K Buy
22,100
+12,700
+135% +$363K ﹤0.01% 9376
2021
Q4 		$347K Buy
+9,400
New +$395K ﹤0.01% 10598

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citadel Advisors's VERV Position: Q3 2025 in Review

Citadel Advisors sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 288,004 shares — an estimated $3.23M sold.

Citadel Advisors first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $48.7M in Q2 2021. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Citadel Advisors reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 288,004 Verve Therapeutics shares in Q3 2025, an estimated $3.23M.
  • Citadel Advisors first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • Citadel Advisors's Verve Therapeutics position peaked at $48.7M in Q2 2021.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.